Immunology Investor Event

Dupixent: Bullous Pemphigoid Number of patients (thousands) Prevalence (1) 52 Biologic eligible 27 26 10 10 63 89 50 50 19 121 Treated with systemic steroids T T T T T 0 10 20 20 30 40 50 60 70 80 90 100 110 120 130 Source: Sanofi analysis OCS: Oral Corticosteroids (1) 18+ population (2) Germany, France, Italy, Spain & United Kingdom 12 Immunology Investor Event US Europe (2) Japan sanofi

View entire presentation